STREPTOMYCIN, an aminoglycoside antibiotic, can reverse the mutant phenotypes of many nonsense and missense mutations in Escherichia coli and in bacteriophage T4. This phenomenon has been called phenotypic suppression, since the mutant phenotype returns after removal of the drug¹. The most likely explanation for phenotypic suppression is that streptomycin promotes mistranslation in vivo, and that acceptable amino acids are inserted into the growing polypeptide chain at the site of the mutant codon. Consistent with this view is the observation that streptomycin causes E. coli ribosomes to mistranslate RNA in vitro^2,3. Streptomycin and neomycin have however been found to have no effect in stimulating ribosomes from eukaryotic cells to mistranslate RNA in vitro^4,5. A subclass of the aminoglycoside antibiotics has been shown^6,7 to stimulate eukaryotic ribosomes to misread RNA. The highly active molecules are distinguished in that they contain the drug fragment paromamine (or 3′-deoxyparomamine). We have therefore examined the capacity of various aminoglycosides to suppress mutations phenotypically in the eukaryotic yeast, Saccharomyces cerevisiae. The results presented here show that paromomycin, which contains paromamine, is capable of phenotypic suppression of the nonsense mutations in S. cerevisiae.